PHASE II
IRB 16058: The Addition of MK-3475 (Pembrolizumab) to Letrozole and Palbociclib in Patients with Metastatic Estrogen Receptor Positive Breast Cancer Who Have Stable Disease But Are Not Responding to Letrozole and Palbociclib.